Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.

Barrie ChubbPalvi GuptaJatin GuptaSolomon NuhohoKlaus KallenbachMichelle Orme

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

Once-daily oral semaglutide 14 mg, as an add-on to basal insulin, is an efficacious treatment for reducing HbA1c and weight and meeting glycaemic targets at 26 ± 4 weeks. Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs.

Keyphrases

type diabetes
physical activity
randomized controlled trial
body mass index
metabolic syndrome
open label
smoking cessation
gestational age
placebo controlled